Just five months after Novo Nordisk launched Wegovy in India, the Danish company has partnered (PDF) with Emcure ...

NVO's new U.S. pricing deal for Ozempic and Wegovy expands access but adds uncertainty to its growth and profit outlook.

Novo Nordisk has partnered with Emcure Pharma to distribute and market its diabetes and weight loss injection semaglutide ...

A NEW weight loss drug may offer a tempting alternative to popular GLP-1 drugs like Ozempic and Wegovy. The once-weekly ...

Poviztra to be sold as 2.4 mg injectable; Emcure becomes first Indian firm with exclusive semaglutide distribution rights ...

Novo Nordisk partners with Emcure to promote Wegovy, following Eli Lilly's recent collaboration with Cipla for tirzepatide in ...

Oral GLP-1 weight loss pills could replace injections by March 2026 at $150 monthly, Medicare chief Dr. Mehmet Oz predicted in a FOX Business appearance.

The White Houes may have struck a deal with Eli Lilly and Novo Nordisk last week to lower the costs of their weight loss ...

A White House deal with Eli Lilly & Co. and Novo Nordisk to lower the prices of their popular obesity medicines, Zepbound and ...

Under the agreement, the Danish drugmaker will sell Poviztra 2.4 milligram (mg) semaglutide injection in India as a separate ...

The deal involves Eli Lilly, which makes Zepbound and Mounjaro, and Novo Nordisk, the maker of Ozempic and Wegovy. The drugs, known as GLP-1 medications, now cost as much as $1350 a month. Under the ...

Danish drugmaker Novo Nordisk announced a partnership with Emcure Pharma on Monday to launch its Poviztra, semaglutide injection 2.4 mg, in India. Poviztra is the second brand of its weight loss drug ...